CD8+ T cells recognize and kill infected and cancerous cells. This recognition is mediated by the T cell receptor complex that is expressed at the T cell surface. This complex structure contains the clonotypic T cell receptor (TCR), the four chains of the CD3 complex d, e, g, z, and CD8 accessory molecules, which are recruited upon activation. The ligand for this complex is the peptide-MHC class I molecule complex (p-MHC) that antigen presenting cells express at their cell surface. The specificity of recognition depends on the binding of the clonotypic TCR to p-MHC. CD8 is also important in this step. This project focuses on the molecular mechanism underlying this multicomponent recognition system. The extracellular domains of each of the components are expressed in a Drosophila expression system, purified and characterized by biochemical means. This system will be used to study the details of CD8/MHC class I interactions and to provide direct evidence for the binding of TCR to CD8. Using a similar approach, we will examine the binding of CD3 chains to each other and to the TCR ab dimer in an attempt to reconstitute the entire extracellular domain of the TCR complex, in vitro. The functional consequences of these associations will be measured directly by surface plasmon resonance on a bilayer membranes. These experiments will use a chelating cage-lipid which allows the capture and orientation of histidine-tagged molecules into bilayers. For all pertinent interactions, crystallization of single components and complexes will be attempted in collaboration with Dr. Ian Wilson. This collaboration will also lead to the mutagenesis of the ab TCR, based on the high resolution structure of TCR/MHC complexes. This mutagenesis will try to identify the structural features required for MHC restriction. The initiation of the production and optimization of new TCR/MHC pairs CD3 and CD8 will also be carried out in the shared protein production facility (shared resource) to provide both laboratories with protein for their immunological and crystallographic studies. Each new TCR will be biologically characterized to limit the effort to the most relevant systems.
The specific aims for the RO1 component are to 1) analyze CD8-pMHC interactions by mutagenesis and SPR and co-crystallization; 2) use SPR to explore direct interactions between TCR and CD8; 3) reconstitute CD3 subunits with TCR in the binding studies; 4) express CD3 subunits for crystallography; 5) do mutagenesis to confirm the interactions between pMHC and TCR suggested by crystallography; and 6) express and characterize new TCR/pMHC pairs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI042267-04
Application #
6328766
Study Section
Allergy and Immunology Study Section (ALY)
Program Officer
Kraemer, Kristy A
Project Start
1997-12-01
Project End
2002-11-30
Budget Start
2000-12-01
Budget End
2001-11-30
Support Year
4
Fiscal Year
2001
Total Cost
$434,884
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Komori, H Kiyomi; Witherden, Deborah A; Kelly, Ryan et al. (2012) Cutting edge: dendritic epidermal ýýýý T cell ligands are rapidly and locally expressed by keratinocytes following cutaneous wounding. J Immunol 188:2972-6
Shore, D A; Issafras, H; Landais, E et al. (2008) The crystal structure of CD8 in complex with YTS156.7.7 Fab and interaction with other CD8 antibodies define the binding mode of CD8 alphabeta to MHC class I. J Mol Biol 384:1190-202
Scherer, Erin M; Zwick, Michael B; Teyton, Luc et al. (2007) Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21:2131-9
Shore, D A; Teyton, L; Dwek, R A et al. (2006) Crystal structure of the TCR co-receptor CD8alphaalpha in complex with monoclonal antibody YTS 105.18 Fab fragment at 2.88 A resolution. J Mol Biol 358:347-54
Cantu 3rd, Carlos; Benlagha, Kamel; Savage, Paul B et al. (2003) The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs. J Immunol 170:4673-82
Apostolopoulos, Vasso; Yu, Minmin; Corper, Adam L et al. (2002) Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J Mol Biol 318:1293-305
Luz, John G; Huang, Mingdong; Garcia, K Christopher et al. (2002) Structural comparison of allogeneic and syngeneic T cell receptor-peptide-major histocompatibility complex complexes: a buried alloreactive mutation subtly alters peptide presentation substantially increasing V(beta) Interactions. J Exp Med 195:1175-86
Rudolph, M G; Huang, M; Teyton, L et al. (2001) Crystal structure of an isolated V(alpha) domain of the 2C T-cell receptor. J Mol Biol 314:1-8
Rudolph, M G; Speir, J A; Brunmark, A et al. (2001) The crystal structures of K(bm1) and K(bm8) reveal that subtle changes in the peptide environment impact thermostability and alloreactivity. Immunity 14:231-42
Degano, M; Garcia, K C; Apostolopoulos, V et al. (2000) A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 12:251-61

Showing the most recent 10 out of 18 publications